Published in Cytometry B Clin Cytom on May 01, 2006
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia (2010) 1.61
FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm. Cell Stem Cell (2012) 1.39
Single-cell mass cytometry for analysis of immune system functional states. Curr Opin Immunol (2013) 1.35
Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma (2008) 1.35
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol (2010) 1.26
Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML. Blood (2011) 1.04
Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. Mol Cancer Ther (2010) 0.94
Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis. J Clin Immunol (2011) 0.91
On systems and control approaches to therapeutic gain. BMC Cancer (2006) 0.90
Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling. Onco Targets Ther (2008) 0.82
Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics. Cancer Manag Res (2011) 0.79
Patient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patterns. Cancer Manag Res (2009) 0.79
Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models. Front Behav Neurosci (2016) 0.76
The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells. J Immunol (2015) 0.75
Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer (2012) 2.54
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol (2005) 2.52
The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res (2005) 2.33
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma (2010) 1.79
Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther (2005) 1.57
The study of epigenetic mechanisms based on the analysis of histone modification patterns by flow cytometry. Cytometry A (2013) 1.43
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol (2007) 1.40
Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. J Clin Oncol (2011) 1.29
Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations. Cytometry A (2005) 1.24
The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol (2004) 1.23
A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res (2005) 1.10
Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood (2008) 1.08
Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study. Int J Radiat Oncol Biol Phys (2006) 1.02
Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res (2004) 1.01
Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen. Clin Cancer Res (2006) 1.00
A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol (2010) 0.97
Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells. J Acquir Immune Defic Syndr (2011) 0.96
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Invest New Drugs (2010) 0.92
Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol (2004) 0.91
Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry. Toxicol Pathol (2008) 0.91
Disruption of the endoplasmic reticulum and increases in cytoplasmic calcium are early events in cell death induced by the natural triterpenoid Asiatic acid. Apoptosis (2006) 0.90
The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. Hum Genet (2007) 0.90
Hedgehog pathway signaling in cervical carcinoma and outcome after chemoradiation. Cancer (2011) 0.90
Emerging applications of flow cytometry in solid tumor biology. Methods (2012) 0.88
A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treat (2007) 0.87
A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Invest New Drugs (2011) 0.84
Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Support Care Cancer (2002) 0.83
Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosis. PLoS One (2012) 0.83
NKIAMRE, a novel conserved CDC2-related kinase with features of both mitogen-activated protein kinases and cyclin-dependent kinases. Biochem Biophys Res Commun (2003) 0.83
Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancer. Mol Pharmacol (2009) 0.82
Heterogeneity and power in clinical biomarker studies. J Clin Oncol (2009) 0.79
Cytometry of intracellular signaling: from laboratory bench to clinical application. Methods Cell Biol (2011) 0.79
Whole blood processing for measurement of signaling proteins by flow cytometry. Curr Protoc Cytom (2008) 0.79
Gene expression profiling of adenosine triphosphate-binding cassette transporters in response to K-ras activation and hypoxia in human pancreatic cancer cell cultures. Pancreas (2009) 0.78
Outcome of adjuvant therapy in biliary tract cancers. Am J Clin Oncol (2015) 0.77
Identification of hypoxic cells using an organotellurium tag compatible with mass cytometry. Angew Chem Int Ed Engl (2014) 0.76
Response to letter 'outcome of second-line chemotherapy for biliary tract cancer'. Eur J Cancer (2012) 0.75
A phase I study of elesclomol sodium in patients with acute myeloid leukemia. Leuk Lymphoma (2016) 0.75
Whole blood measurement of histone modifications linked to the epigenetic regulation of gene expression. Curr Protoc Cytom (2015) 0.75